Antibiotics Market Share

APAC Market Statistics

The Asia Pacific antibiotics market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2037. It is backed by the growing prevalence of infectious diseases, increasing consumption of antibiotics by regional population, significantly growing population, and growing healthcare expenditure in the region. For instance, around 4.2 billion people, or 61% of the world's population, reside in the Asia Pacific region.

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of antibiotics is estimated at USD 53.91 billion.

The antibiotics market size was valued at USD 50.55 billion in 2024 and is expected to cross USD 142.07 billion by the end of 2037, expanding at more than 8.2% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of respiratory diseases, surge in drug combinations over mono-therapy, escalation in urinary tract infections (UTIs) will drive the market growth.

Asia Pacific is anticipated to hold majority industry share by 2037, backed by growing prevalence of infectious diseases, increasing consumption of antibiotics by regional population, significantly growing population, and growing healthcare expenditure in the region.

The major players in the market include F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd., Pfizer Inc., Abbott Laboratories, Merck & Co., Inc., Lupin Limited, Melinta Therapeutics, LLC, Bayer AG.

Antibiotics Market Share